What the FDA labels say about taking them together
Apixaban and atazanavir
Atazanavir's FDA label of August 6, 2025 names apixaban in its drug interactions section; the apixaban labels PlainMeds reads (2) do not name atazanavir. The atazanavir label: “… CYP3A4/P-gp inhibitor, may result in an increased risk of bleeding. Refer to apixaban dosing instructions for coadministration with strong CYP3A4 and P-gp inhibitors in the apixaban prescribing information. …”
Check it at the source: the apixaban FDA label on DailyMed (effective April 24, 2026, Cardinal Health 107, LLC); the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited).
What does the apixaban label say about atazanavir?
Apixaban's label (effective April 24, 2026) and its 1 other brand-application label do not name atazanavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ELIQUIS), NDA202155 (Bristol Myers Squibb), as published by Cardinal Health 107, LLC, effective April 24, 2026 (SPL set a454cd24-0c6d-46e8-b1e4-197388606175), via openFDA; the full label on DailyMed
What does the atazanavir label say about apixaban?
Atazanavir label, drug interactionsConcomitant Drug Class/Specific Drugs: rivaroxaban apixaban; Effect on Concentration of Atazanavir or Concomitant Drug: Atazanavir with ritonavir ↑ rivaroxaban Atazanavir ↑ rivaroxaban Atazanavir with ritonavir ↑ apixaban Atazanavir ↑ apixaban; Clinical Comment: Coadministration of atazanavir with ritonavir, a strong CYP3A4/P-gp inhibitor, and rivaroxaban is not recommended, as it may result in an increased risk of bleeding. Coadministration of atazanavir, a CYP3A4 inhibitor, and rivaroxaban may result in an increased risk of bleeding. Close monitoring is recommended when atazanavir is coadministered with rivaroxaban. …
Reyataz label (E.R. Squibb & Sons, L.L.C., December 5, 2024), drug interactionsConcomitant Drug Class/Specific Drugs: apixaban; Effect on Concentration of Atazanavir or Concomitant Drug: REYATAZ with ritonavir ↑ apixaban; Clinical Comment: Concomitant use of REYATAZ with ritonavir, a strong CYP3A4/P-gp inhibitor, may result in an increased risk of bleeding. Refer to apixaban dosing instructions for coadministration with strong CYP3A4 and P-gp inhibitors in the apixaban prescribing information.
Source: FDA drug label (Reyataz, NDA021567), E.R. Squibb & Sons, L.L.C., effective December 5, 2024 (SPL set 165cff62-b284-4a27-a65d-9ec8a5bfcdd8), via openFDA
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Apixaban | Atazanavir | |
|---|---|---|
| Labeled for | Atrial fibrillation, Blood clots (DVT and PE), Stroke prevention | HIV |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $5.52 per tablet 5 mg tablet | $2.23 per capsule 300 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once